Meyron

Reference summary — not medical advice or a personal risk estimate.

Organ transplant / immunosuppressants

Long-term immunosuppression after organ transplant is associated with elevated cancer risk.

Also known as: immunosuppressant medication, organ transplant drugs

What this does NOT mean

Finding a factor documented in this product category does not establish that ordinary use of organ transplant / immunosuppressants causes cancer. It means research — through regulatory testing, recall records, or IARC review — has found that chemical present in this category. Whether it matters for you depends on formulation, dose, frequency, and route of exposure.

What has been documented

  • Azathioprine
    IARC Group 1
    Exposure from · high confidence

    Immunosuppressant used post-transplant; IARC Group 1.

    Evidence source: IARC

  • Exposure from · high confidence

    Immunosuppressant; IARC Group 1.

    Evidence source: IARC

How to read this page

A factor appearing on this page means it has been documented in this product category — through EPA / FDA testing, IARC monographs, or regulatory recall records. Whether it presents a meaningful personal risk depends on the specific formulation, dose, and how you're exposed. Click any factor to read what science actually says about it, and where.